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Abstract
Herpes simplex virus type 1 (HSV‑1) -based amplicon vectors have a transgene capacity of up to 150
kbp and can efficiently transduce many different cell types in culture and in vivo without causing
cytopathic effects. However, these vectors do not support long-term transgene expression.
Adeno-associated virus type 2 (AAV‑2)has the capacity to integrate its genome into a specific site on
human chromosome 19, but AAV‑2-derived gene therapy vectors have a transgene capacity of only 4.5
kb. To combine the large transgene capacity of HSV‑1 with the potential for site-specific genomic
integration and long-term transgene expression of AAV‑2, HSV/AAV hybrid vectors have been
developed. This review describes the design, applications and limitations of these hybrid vectors.
However, as HSV‑1 is a full helper virus for AAV‑2 replication, the main focus is the analysis of the
molecular mechanisms of interaction between the two viruses. The knowledge of these interactions will
have direct implications on the design of novel HSV/AAV hybrid vectors.
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Herpes simplex virus type 1 (HSV‑1)/adeno ‑
associated virus (AAV) hybrid vectors have been 
designed to overcome the limitations of the par‑
ent vector systems, in particular the instability of 
transgene expression of HSV‑1 amplicon vectors 
and the small transgene capacity of AAV vec‑
tors. Indeed, HSV/AAV hybrid vectors have been 
demonstrated to support site‑specific integration 
in human chromosome 19 and stable transgene 
expression [1,2], even with transgenes as large as 
100 kbp [3]. Although other considerable prob‑
lems exist, including off‑target integration and 
vector‑induced immune responses, one of the 
major hurdles to the use of these hybrid vectors 
has been the low titers of vector stocks. As HSV‑1 
is a full helper virus for AAV replication, we are 
studying the molecular mechanisms of interac‑
tion between replicating HSV‑1 and AAV in 
co‑infected cells in detail. This may allow us to 
identify and overcome restrictions in replication 
efficiency of HSV‑1 in the presence of replica‑
tive AAV and support the design of novel hybrid 
vectors that tolerate the presence of multiple ori‑
gins of DNA replication (oris) from HSV‑1 and 
AAV on the same vector genome. This article 
focuses on the description of HSV‑1 and AAV 
interactions and the impact of these interactions 
on HSV/AAV hybrid vector production.
Adeno-associated virus type 2
Adeno‑associated virus type 2 (AAV‑2) is a wide‑
spread, nonpathogenic human parvovirus. The 
virion has a diameter of approximately 20 nm 
and consists of an icosahedral capsid, which is 
composed of a mixture of virion proteins (VPs) 
1, 2 and 3. The viral genome is a linear, ssDNA 
of 4.7 kb containing 145‑base inverted terminal 
repeats (ITRs) at both ends, flanking two clus‑
ters of genes, rep and cap, which are controlled 
by three different promoters, p5, p19 and p40 
(Figure 1A) [4,5]. The ITRs can form T‑shaped 
secondary structures; they contain the Rep‑
binding site (RBS) and the terminal resolution 
site (TRS), which together act as a minimal ori 
and as a packaging signal [6–9]. The p5 promoter 
controlling the synthesis of the large Rep pro‑
teins, Rep68 and Rep78, also contains a RBS [10], 
which is involved in the Rep‑mediated regulation 
of p5 activity [11,12], as well as a functional TRS 
[13]. Indeed, the TRS and RBS in p5 have been 
reported to have replication origin activity in the 
presence of both adenovirus (Ad) and HSV‑1 
helper functions [14–16]. The small Rep proteins, 
Rep40 and Rep52, are translated from spliced 
and unspliced mRNAs that both originate from 
the p19 promoter. All three capsid proteins, VP1, 
VP2 and VP3, are translated from two alterna‑
tively spliced mRNA species that originate from 
a single promoter, p40 [17]. The Kleinschmidt 
group has recently identified an alternative open 
reading frame (ORF) of the cap gene, which 
encodes an AAV‑2 protein termed ‘assembly acti‑
vating protein’ (AAP). AAP targets newly syn‑
thesized capsid proteins to the nucleolus where 
capsid assembly occurs and, in addition, it fulfils 
a function in the assembly reaction itself [18].
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Adeno‑associated virus type 2 infects the 
cell via receptor‑mediated endocytosis, with 
heparan sulfate proteoglycan acting as primary 
receptor for cell attachment [19] and FGF recep‑
tor‑1 [20], integrins aVb1 and aVb5 [21], the 
36/67‑kDa laminin receptor [22] and HGF 
receptor [23] acting as co‑receptors. Following 
receptor binding, AAV‑2 enters the cell via 
a dynamin‑dependent clathrin‑coated pit 
endocytosis pathway. AAV‑2 escapes from 
the late endosome and delivers the genome 
into the nucleus [24–29]. In the nucleus, the 
AAV‑2 genome is either replicated or becomes 
latent, depending on the presence or absence 
of a helper virus. In the presence of a helper 
virus, AAV‑2 genome replication follows a 
single‑strand displacement mechanism termed 
the ‘rolling hairpin model’ of DNA replica‑
tion, with the ITRs acting as primers for 
second‑strand synthesis [30–32]. 
ITR ITR
p5 p19 p40 pA
rep cap
rep 78
rep 68
rep 52
rep 40
VP1
VP2/VP3
AAP
pac pac pacori ori ori
TRL UL IRL IRS US TRS
Figure 1. Virus genomes (not to scale). (A) The adeno-associated virus type 2 genome is a linear, ssDNA of 4.7 kb containing 
145-base ITRs at both ends, flanking two clusters of genes, rep and cap. The ITRs contain the ori and the pac signal. The rep genes 
encode four overlapping proteins, Rep78, 68, 52 and 40, from two different promoters, p5 and p19. The cap gene encodes four 
overlapping proteins, VP1, 2, 3 and AAP from a single promoter, p40. VP1 is translated from an ATG start codon at position 2203. 
Translation of VP2 starts from an ACG start codon (position 2614) located 66 codons upstream of the VP3 ATG start codon (position 
2809). Translation of AAP starts from a CUG codon located at position 2729. All rep and cap transcripts share a common pA signal. 
(B) The herpes simplex virus type 1 (HSV-1) genome (152 kbp) is composed of U
L
 and U
S
 segments, which are each flanked by inverted 
repeats TR
L
, IR
L
, IR
S
 and TR
S
. The DNA cleavage/packaging signals (pac) and the ori are indicated. Ori and pac are the sole cis-acting 
elements necessary for HSV-1 replication and packaging. The HSV-1 genome encodes more than 85 genes in a controlled fashion with 
three temporal phases, immediate-early, early and late. 
AAP: Assembly-activating protein; IR
L
: Internal repeat long; IR
S
: Internal repeat short; ITR: Inverted terminal repeat; ori: Origin of DNA 
replication; pA: Polyadenylation; pac: Packaging; TR
L
: Terminal repeat long; TR
S
: Terminal repeat short; U
L
: Unique long; U
S
: Unique short; 
VP: Virion protein.
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In the absence of a helper virus, the ITRs and 
either Rep78 or Rep68 can mediate the integra‑
tion of the AAV‑2 genome into a specific site, 
termed AAVS1, on chromosome 19 of human 
cells [33–36]. AAVS1 is closely linked to the 
muscle‑specific genes TNNT1 and TNNI3 [37]. 
AAV-2-based gene therapy vectors
Many of its biological properties, in particu‑
lar the low toxicity and immunogenicity, and 
stability of gene expression, as well as its sim‑
plicity make AAV‑2 an interesting platform 
for vector development [38]. The recombinant 
(r)AAV vector is a bacterial plasmid that con‑
tains a transgene flanked by the AAV‑2 ITRs 
(Figure 2A). Conventionally, the AAV‑2 replicative 
and structural genes (rep and cap) are provided 
in trans from a separate plasmid. Following 
cotransfection of the two plasmids into Ad‑ or 
HSV‑1‑infected cells, the ITR‑flanked trans‑
gene cassette is replicated and single‑stranded 
replication products are packaged into AAV‑2 
capsids. Infectious rAAV particles are separated 
from helper virus particles by density gradient 
centrifugation. There are many variations to 
this general packaging strategy with respect to 
cellular delivery of the three components, the 
rAAV plasmid vector, rep/cap and helper virus 
functions [39–44]. Other recent developments 
in rAAV vector production include the use of: 
helper virus‑free packaging systems [45], affin‑
ity chromatography for vector purification [19,46] 
and the combination of AAV‑2 genomes with 
capsids of other AAV serotypes [47–49]. Other 
AAV vector technologies have been developed 
to increase the transgene capacity [50] or enhance 
transgene expression [51]. 
Recombinant AAV vectors have been used for 
the delivery of therapeutic genes into many dif‑
ferent cell types and tissues. Studies in animal 
models of various diseases, including Parkinson’s 
disease, diabetes and hemophilia B, as well as in 
human clinical trials, have been most promising. 
Some of the target diseases of human clinical 
gene‑therapy trials performed previously using 
rAAV vectors include: cystic fibrosis [52–54], 
hemophilia [55], Parkinson’s disease [56,57] and 
Leber’s congenital amaurosis [58–63].
Adeno‑associated virus‑based vectors also 
have limitations. The small packaging capa city 
does not allow the insertion of large regulatory 
sequences, genomic transgene sequences or even 
some cDNAs. Furthermore, rAAV vector genomes 
can persist for long periods and support long‑
term gene expression, but this is not due to site‑
specific integration, as rep is in general removed 
from the ITR cassette to make room for transgene 
sequences. Adverse effects have also been observed 
in some of the clinical gene‑therapy trials, such as 
in a clinical trial for hemophilia B; unexpected 
liver toxicity was observed and was due to a cyto‑
toxic T‑lymphocyte response to rAAV‑transduced 
hepatocytes [55].
Herpes simplex virus type 1
Herpes simplex virus type 1 is a member of the 
family Herpesviridae and an important human 
pathogen. The HSV‑1 virion has a diameter 
+ rep–cap + 
helper (virus) functions
+ helper (virus) functions
+ helper (virus) functions
Figure 2. Virus vectors. (A) Recombinant 
adeno-associated virus (AAV) vectors are 
bacterial plasmids that contain a transgene 
cassette, which is flanked by inverted terminal 
repeats. Replication of these vectors and 
packaging into AAV particles depend on AAV 
rep/cap expression and helper virus functions 
provided by adenovirus or herpes simplex virus 
type 1 (HSV-1). (B) The standard HSV-1 
amplicon vector is a bacterial plasmid that 
contains the HSV-1 ori and pac signals and a 
transgene cassette of up to 150 kbp of DNA. 
(C) In addition to the standard HSV-1 amplicon 
elements, HSV/AAV hybrid vectors contain a 
transgene cassette that is flanked by AAV 
inverted terminal repeats and the AAV rep 
gene. Replication and packaging of HSV-1 
amplicon and HSV/AAV hybrid vectors depend 
on HSV-1 helper functions. The genetic 
elements are coded as follows: green: 
transgene; light blue: AAV-2 inverted terminal 
repeats; dark blue: AAV-2 rep gene; 
purple: HSV-1 ori; pink: HSV-1 pac signal.
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of approximately 300 nm and consists of an 
icosadeltahedral capsid containing the viral 
genome. The capsid, which has a diameter 
of approximately 100 nm, is surrounded by a 
proteinaceous layer, the tegument, which in 
turn is enclosed by a lipid envelope carrying 
the viral glycoproteins. The virus genome is a 
dsDNA of approximately 152 kbp (Figure 1B). 
HSV‑1 infection starts with the attachment of 
virion glycoproteins C and B to glycosamino‑
glycans, preferentially heparan sulfate, on 
the cellular surface of skin or mucosa [64–68]. 
Glycoproteins B, D and the gH–gL complex 
mediate fusion of the virion envelope with the 
cell membrane [69–71]. At least three to four spe‑
cific cell surface receptors that interact with 
gD have been identified and designated herpes 
virus entry mediators [72–76]. After entry into 
the cytoplasm, the capsid and tegument pro‑
teins are transported along microtubules to the 
nuclear pores [77] where the DNA is released 
into the nucleoplasm [78,79].
Herpes simplex virus type 1 encodes more 
than 80 genes. The first genes to be expressed 
upon infection are the immediate‑early (IE) 
genes, which encode several transactivator 
proteins, such as ICP0 and ICP4; these initi‑
ate transcription of the early genes and some 
late genes. Early gene products comprise the 
viral DNA replication factors that initiate viral 
DNA synthesis. Replication of the viral DNA 
then stimulates expression of the late genes, 
which encode structural virion proteins. HSV‑1 
DNA replication occurs in nuclear domains 
termed replication compartments (RCs) [80,81]. 
Replication starts at the ori and produces large, 
branched concatemers of head‑to‑tail linked 
genomes [82,83]. Concatemers are cleaved into 
unit‑length genomes at the cleavage/packag‑
ing signals (pac) after filling preformed cap‑
sids [84–86]. Different models of HSV‑1 mat‑
uration, envelopment and egress have been 
proposed. One model suggests that the virus 
acquires some tegument proteins and a primary 
envelope when budding through the inner 
nuclear membrane. The enveloped virions fuse 
with the outer nuclear envelope, thereby releas‑
ing free nucleocapsids at the cytoplasm that 
will be re‑enveloped in a golgi‑related com‑
partment. Re‑enveloped virion particles are 
then secreted by a vesicular route [87]. Another 
model proposes two distinct pathways. The 
first pathway involves envelopment at the inner 
nuclear membrane followed by intraluminal 
transport to golgi cisternae, where transport 
vacuoles are formed. Alternatively, capsids leave 
the nucleus via impaired nuclear pores and are 
enveloped at the cytoplasmic membranes of the 
rough endoplasmic reticulum [88,89].
The life cycle of HSV‑1 is characterized by pro‑
ductive replication in epithelial cells of the mucosa 
and life‑long latent infection in sensory neurons; 
from there the virus can sporadically reactivate 
and enter a new lytic replication cycle [90]. 
HSV-1-based gene therapy vectors
Two fundamentally different HSV‑1‑based vec‑
tor systems, recombinant and amplicon, have 
been developed to exploit the numerous bio‑
logical properties that make this virus such an 
efficient gene‑delivery vehicle. Recombinant 
HSV‑1 vectors are created by replacing one or 
several virus genes with transgene sequences. 
Depending on the viral genes that are replaced, 
rHSV‑1 vectors can be replication‑competent, 
replication‑defective or replication‑conditional. 
Replication‑conditional, oncolytic rHSV‑1 vec‑
tors, rHSV1716 and rHSV‑G207, have been 
assessed in human patients with high‑grade 
gliomas in Phase I clinical trials [91,92].
Amplicon vectors are bacterial plasmids that 
contain a transgene cassette and only two HSV‑1 
cis elements, an ori and a pac signal, but no viral 
genes (Figure 2B). These two HSV‑1 elements are 
sufficient to support replication of the vector 
DNA and packaging of the concatemeric rep‑
lication products into virions in the presence of 
HSV‑1 helper functions. Helper functions can 
be provided by replication‑conditional HSV‑1 
helper viruses [93] or replication‑competent/con‑
ditional, packaging‑defective HSV‑1 genomes 
cloned as sets of cosmids [94] or bacterial artifi‑
cial chromosomes [95–97]. Epstein and co‑workers 
developed a novel strategy for producing large 
amounts of vector stocks with very low helper 
virus contamination [98,99]. This system uses a 
recombinant HSV‑1 helper virus, which contains 
a pac signal flanked by loxP sites. This recom‑
binant helper virus is replication‑ and packaging‑
competent in normal cells, but when amplicon 
packaging is performed in cre‑recombinase‑
expressing cells, the pac signals are efficiently 
deleted from the helper virus genomes, thereby 
preventing their packaging into virus particles. 
Amplicon vectors conserve most of the proper‑
ties of the parental virus, including a broad host 
range, the capability to transduce both divid‑
ing and nondividing cells, and a large transgene 
capacity (up to 150 kbp). This large transgene 
capacity allows the incorporation of genomic 
sequences as well as cDNA, large transcrip‑
tional regulatory sequences for cell type‑specific 
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expression, multiple transgene cassettes or genetic 
elements from other viruses to create hybrid vec‑
tors. Although HSV‑1 amplicon vectors have not 
yet entered clinical trials, they have been used in 
many different cell types, tissues, target diseases 
and animal models [100,101]. The major limita‑
tions of HSV‑1 amplicon vectors are their lack 
of ability to mediate stable transgene expression 
and the difficulties of scaling up production of 
helper virus‑free vector stocks. 
HSV/AAV hybrid vectors
Herpes simplex virus/AAV hybrid vectors have 
been designed to overcome the limitations of 
HSV‑1 amplicon vectors (transient gene expres‑
sion) and AAV‑based vectors (small transgene 
capacity) [1–3,102,103]. In addition to the standard 
HSV‑1 amplicon elements, HSV/AAV hybrid 
vectors contain the AAV‑2 rep gene and a trans‑
gene that is flanked by AAV‑2 ITRs (Figure 2C). 
Since HSV/AAV hybrid vectors can be packaged 
into HSV‑1 virions, they conserve the proper‑
ties of the HSV‑1 amplicon, including high effi‑
ciency of gene transfer, large transgene capacity 
and availability of a helper virus‑free packaging 
system. However, after delivery into the host cell 
nucleus, the vector has the potential to act like 
AAV‑2, with rep‑mediated site‑specific integra‑
tion of the ITR‑flanked transgene cassette into 
the AAVS1 element of human chromosome 19. 
Following infection of cultured human glioma 
cells, HSV/AAV hybrid vectors support trans‑
gene expression significantly longer than standard 
amplicons [102]. Moreover, Heister and colleagues 
demonstrated that these vectors can indeed mediate 
site‑specific integration at AAVS1 [1]. The junctions 
between AAVS1 and the hybrid amplicon vector‑
delivered AAV‑2 ITR cassette were similar to those 
that had been identified in cells infected with wild‑
type AAV‑2 [33–35,104–107], baculo virus/AAV hybrid 
vectors [108] or Ad/AAV hybrid vectors [109,110]. 
Similar results were obtained by Wang and col‑
leagues who have used human glioma cells (gli36) 
and primary myoblasts [2].
In summary, inserting AAV‑2 rep and ITRs into 
the HSV‑1 amplicon vector considerably improved 
the frequency of stable transgene expression in 
various proliferating human cell types. However, 
two hurdles to using HSV/AAV hybrid vectors 
include the low packaging efficiency and low tit‑
ers due to rep expression, which inhibits HSV‑1 
DNA replication [1,2]. A detailed knowledge of 
the interactions between HSV‑1 and AAV‑2 may 
allow us to overcome this hurdle and support 
the design of novel HSV/AAV‑based hybrid vec‑
tors that can mediate highly efficient and precise 
site‑specific integration of therapeutic transgenes 
into the human genome without compromising 
the vector titers.
Interactions between AAV-2, HSV-1 & the 
host cell
HSV‑1 helper functions for 
AAV‑2 replication
Replication and packaging of HSV/AAV 
hybrid amplicon vectors depends on the pres‑
ence of HSV‑1 helper factors, which, however, 
not only interact with the HSV‑1 elements on 
the hybrid vectors, but, since HSV‑1 is a helper 
virus for AAV‑2, also interact with the AAV‑2 
elements present. A profound understanding of 
the mechanisms by which HSV‑1 helper factors 
support AAV replication is therefore crucial for 
the rational design of improved HSV/AAV vec‑
tors. The mole cular mechanisms by which helper 
factors induce AAV‑2 replication have been 
most thoroughly studied for the helper viruses 
Ad and HSV‑1, while the helper effects of other 
viruses such as papilloma virus [111,112] and vac‑
cinia virus [113] remain much less‑well defined. 
Comparing the helper activities provided by 
Ad and HSV‑1 allows us to better identify the 
key features of AAV‑2’s helper dependence and 
provides an intriguing illustration of how two 
different helper strategies ultimately achieve the 
same end, for example, reactivation and pro‑
ductive replication of AAV‑2. The helper effect 
of Ad on AAV‑2 replication is mediated by five 
early gene products, specifically E1A, E2A, the 
E1B55K/E4ORF6 complex and the virus‑asso‑
ciated (VA)I RNA. Ad E1A function is required 
for transactivation of the p5 rep promoter [114], 
as well as for the induction of S phase [114–118]. 
The induction of S phase and the concomitant 
synthesis of cellular DNA replication factors are 
likely needed for AAV‑2 DNA replication in 
the presence of Ad helper virus [119]. Consistent 
with this, cellular DNA polymerases seem to be 
responsible for AAV‑2 replication in the presence 
of Ad [8,120–122]. Ad E2A is a ssDNA‑binding 
protein that supports AAV‑2 replication by 
two distinct mechanisms: first, E2A stimulates 
transcription from AAV‑2 promoters and may 
be involved in mRNA transport and stability 
[123,124]. Second, E2A is preferentially used for 
AAV‑2 DNA replication in place of the cel‑
lular ssDNA‑binding protein, replication pro‑
tein A (RPA) [125]. The Ad E1B55K/E4ORF6 
complex enhances AAV‑2 replication and 
rAAV‑2‑mediated transduction by enhancing 
second‑strand synthesis [126,127], an effect that 
has been shown to be mediated by the ability of 
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E1B55K/E4ORF6 to degrade the Mre11/Rad50/
Nbs1 complex [128]. This complex is a conserved 
multiprotein complex involved in DNA damage 
sensing, signaling and repair [129], and its sensing 
and processing of AAV‑2 genome ends has been 
shown to be inhibitory to AAV‑2 second‑strand 
synthesis and DNA replication [128,130]. Finally, 
Ad VAI RNA facilitates the initiation of AAV‑2 
protein synthesis by prevention of the interferon‑
induced host cell shut‑off of translation [131,132]. 
In summary, the helper functions provided by 
Ad help AAV‑2 to overcome its deficits in gene 
expression and DNA replication by the activa‑
tion of AAV‑2 gene expression (via E1A, E2A and 
VAI RNA), by driving the host cell into S phase 
and thereby inducing the cellular DNA replica‑
tion machinery (via E1A), by directly participat‑
ing in AAV‑2 DNA replication (via E2A) and by 
overcoming cellular barriers to AAV‑2 replica‑
tion imposed by the DNA damage response (via 
E1B55K/E4ORF6).
Similar to the helper functions provided by Ad, 
HSV‑1 helper functions are also mainly involved 
in the processes of AAV‑2 gene expression and 
DNA replication (for an overview see Figure 3). 
Integrated, latent AAV‑2 genomes are transcrip‑
tionally silent. In the case of the p5 promoter con‑
trolling the expression of the large Rep proteins 
Rep68 and Rep78, the repression was shown to be 
due to the Rep68 and Rep78 proteins themselves 
and to cellular factors including YY1 [11,114,133,134]. 
An essential first step in productive AAV‑2 rep‑
lication is the expression of the large Rep pro‑
teins. Rep68 and Rep78 are not only required 
for viral DNA replication, but also for efficient 
transcription from the p19 promoter controlling 
the expression of the small Rep proteins, Rep40 
and Rep52, as well as for transcription from the 
p40 promoter, directing expression of the cap‑
sid proteins VP1, VP2 and VP3 [12]. Activation 
of the p5 promoter can therefore be considered 
the initiating event for productive AAV‑2 rep‑
lication. In analogy to Ad E1A, the HSV‑1 IE 
gene product ICP0 was shown to transactivate 
transcription from the p5 promoter, resulting in 
Rep68 and Rep78 synthesis [135]. However, ICP0 
also induced the synthesis of Rep40 and Rep52, 
which is controlled by the p19 promoter. It is cur‑
rently not known if the induction of Rep40 and 
Rep52 synthesis by ICP0 involves a direct activa‑
tion of the p19 promoter by ICP0 or if the effect 
is indirectly mediated by the Rep68 and Rep78 
proteins [12,135]. Although ICP0 is considered a 
promiscuous transactivator of gene expression 
[136], the effect on rep expression seems specific, 
in that ICP0 does not activate cap expression [135]. 
The induction of rep expression is strictly depend‑
ent on the E3 ubiquitin ligase activity of the ICP0 
RING‑finger domain and on proteasome activity, 
Figure 3. AAV‑2–HSV‑1 coinfection. See 
legend on facing page.
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suggesting that derepression of the p5 promoter 
involves the ICP0‑induced degradation of one or 
several cellular factors [135,137]. Activation of the 
p5 promoter by ICP0 also involves the interac‑
tion of ICP0 with the deubiquitylating enzyme 
USP7/HAUSP, which, however, is not essen‑
tial [135,137]. It was recently shown that transac‑
tivation of rep expression by ICP0 can be further 
enhanced by the presence of two other HSV‑1 IE 
proteins, ICP4 and ICP22 [138]. On their own, 
ICP4 stimulates rep expression only marginally, 
while ICP22 has no effect [138]. ICP4 is a transac‑
tivator protein essential for HSV‑1 replication and 
is required for expression of several early and late 
genes [139]. ICP4 may enhance the effect of ICP0 
by physically interacting with the latter or by 
direct binding to degenerate binding sites in the 
p5 promoter [140,141]. ICP22 stimulates the expres‑
sion of some HSV‑1 late genes and is involved in 
the alteration of cell‑cycle regulatory proteins and 
in the modification of cellular RNA polymerase 
II [142,143]. The molecular mechanism by which 
ICP22 contributes to transactivation of rep 
expression remains, however, unknown [138]. rep 
expression from AAV‑2 genomes delivered into 
the cell by infection or transfection is less tightly 
repressed than that of AAV‑2 genomes integrated 
into the host cell genome. Consequently, low‑level 
rep expression can be observed even in the absence 
of helper virus, which is, however, significantly 
enhanced by the presence of ICP0, ICP4 and 
ICP22 [138]. AAV‑2 replication upon infection 
or transfection is therefore much less dependent 
on rep transactivation by ICP0, ICP4 and ICP22 
than reactivation of latent virus [138,144].
Once Rep68 and Rep78 proteins are pro‑
duced in sufficient amounts, they are thought to 
transactivate expression from the p19 and p40 
promoters, leading to synthesis of Rep40/Rep52 
and the capsid proteins, respectively [12]. Rep40 
and Rep52, in turn, prevent the autorepressive 
activity of Rep68 and Rep78 on the p5 promoter, 
resulting in high levels of Rep68 and Rep78 dur‑
ing lytic replication [12]. Simultaneously, the large 
Rep proteins initiate AAV‑2 DNA replication by 
binding to the RBSs in the ITR and p5 oris fol‑
lowed by nicking at the TRSs, the latter creating 
primers for repair synthesis of the ITRs [145]. It 
is at this stage of its replication cycle that AAV‑2 
again depends on help from HSV‑1, specifically 
the presence of the ssDNA‑binding protein ICP8 
(encoded by UL29), the helicase–primase com‑
plex (encoded by UL5, UL8 and UL52) and 
the DNA polymerase holoenzyme (encoded by 
UL30 and UL42) [138]. It is thought that during 
AAV‑2–HSV‑1 coinfection, the AAV‑2 DNA is 
replicated by the HSV‑1 replication machinery 
assembling on the AAV‑2 oris [120]. In analogy 
to the HSV‑1 ori‑binding protein UL9 [146], Rep 
probably triggers the assembly of the replication 
machinery by binding to the RBSs within the 
AAV‑2 oris. In the next step, Rep68 and Rep78 
are thought to recruit ICP8 through a direct pro‑
tein–protein interaction, which in turn stimulates 
Rep DNA‑binding and nicking activity [147,148]. 
The Rep68/78‑ICP8 complex is then thought to 
recruit the helicase–primase complex, as well as 
the DNA polymerase holoenzyme. Among the 
HSV‑1 replication factors involved in AAV‑2 
replication, ICP8 can certainly be considered a 
key helper factor, since its presence is crucial to 
processive AAV‑2 DNA replication. The func‑
tion of ICP8 presumably lies in its ability to 
stabilize ssDNA and to hold the replication fork 
in an extended conformation [149], as well as in 
its ability to act as a scaffolding protein for the 
recruitment of the helicase–primase complex and 
the polymerase holoenzyme [90,147]. Consistent 
with a key role in the helper activity, the mere 
addition of purified ICP8 to extracts from unin‑
fected HeLa cells is sufficient to support in vitro 
AAV‑2 DNA replication [148]. The function of 
the helicase–primase complex in AAV‑2 replica‑
tion appears to be somewhat more complicated. 
Figure 3. AAV‑2–HSV‑1 coinfection. (A) HSV-1 entry phase. HSV-1 infects a cell that carries a latent, integrated AAV-2 genome. 
(B) Immediate-early (IE) phase. Upon delivery of the HSV-1 genome to the nucleus, HSV-1 IE gene expression begins, including ICP0, 
ICP4 and ICP22, which together transactivate HSV-1 early genes and the AAV-2 rep gene. (C) Early phase. Triggered by the HSV-1 IE 
gene products, AAV-2 rep expression and HSV-1 early gene expression ensue. The synthesized proteins include the components of the 
DNA replication machinery, specifically the large AAV-2 Rep proteins Rep68 and Rep78, the HSV-1 origin of replication (ori)-binding 
protein UL9, the HSV-1 ssDNA-binding protein ICP8 (UL29), the HSV-1 HP complex (UL5/8/52) and the HSV-1 DNA pol holoenzyme 
(UL30/42). (D) Assembly of DNA replication complexes in pre-replicative sites. UL9 binds to the HSV-1 ori and recruits HSV-1 ICP8, the 
HSV-1 HP complex and the HSV-1 DNA pol. AAV-2 Rep68 and Rep78 bind to the AAV-2 oris (ITR and p5) and recruit HSV-1 ICP8, the 
HSV-1 HP complex and the HSV-1 DNA pol. (E) DNA replication phase. Processive HSV-1 and AAV-2 DNA replication lead to the 
formation of replication compartments, which remain spatially separate entities and recruit distinct sets of viral and cellular proteins.  
(F) Inhibition of HSV-1 DNA replication by AAV-2. The accumulation of high concentrations of AAV-2 Rep68 and Rep78 proteins results 
in inhibition of HSV-1 DNA replication, which in turn limits the competition of HSV-1 DNA for replication factors and cellular resources, 
and thereby confers a competitive advantage to AAV-2. In (E & F), the blue globular structures represent AAV-2 RCs and the yellow 
represent HSV-1 RCs. 
AAV-2: Adeno-associated virus type 2; DNA pol: DNA polymerase; HP: Helicase–primase; HSV-1: Herpes simplex virus type 1;  
RC: Replication compartment.
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On one hand, the helicase–primase complex is 
not required for in vitro AAV‑2 DNA replication 
[8,148]. On the other hand, all three components, 
UL5, UL8 and UL52, are strictly required for 
in vivo AAV‑2 replication (i.e., in infected or 
transfected cells) [138,144]. More specifically, the 
role of the helicase–primase complex for in vivo 
AAV‑2 replication can be divided into its role as 
a scaffolding protein and its role as an enzyme. 
For its role as a scaffolding protein in the assem‑
bly of replication complexes, neither the helicase 
activity of UL5, nor the primase activity of UL52 
are required [150]. By contrast, the UL5 helicase, 
but not the UL52 primase activity, is required 
for efficient in vivo AAV‑2 DNA replication [150]. 
While the dispensability of the UL52 primase 
activity is consistent with the fact that AAV‑2 
DNA synthesis proceeds exclusively via leading‑
strand synthesis [145], the requirement for the 
5´ –3´ helicase activity of UL5 in addition to the 
3´–5´  helicase activity of Rep is less obvious. The 
role of the HSV‑1 DNA polymerase in AAV‑2 
replication has remained somewhat controversial. 
On one hand, the findings that the AAV‑2 repli‑
cation complexes extracted from AAV‑2–HSV‑1‑
coinfected cells mainly contain the HSV‑1 DNA 
polymerase [120] and that the HSV‑1 DNA 
polymerase holoenzyme is capable of replicating 
AAV‑2 DNA in a reconstituted in vitro system [8] 
support the notion that AAV‑2 DNA is replicated 
by the HSV‑1 DNA polymerase. On the other 
hand, the requirement for the HSV‑1 polymerase 
is not absolute, in that AAV‑2 DNA replication 
can also be observed in the absence of the HSV‑1 
DNA polymerase, although at reduced levels 
[138,144]. These observations presumably reflect the 
fact that the extent to which AAV‑2 DNA syn‑
thesis is mediated by the HSV‑1 DNA polymer‑
ase and cellular DNA polymerases depends on 
their respective abundance. In the case of the 
Ad helper virus, E1A directs the host cell into 
S phase, inducing cellular polymerase activity, 
while HSV‑1 helper virus provides polymerase 
activity via the UL30 and UL42 gene products. 
In cells transfected with only the minimal HSV‑1 
helper factors UL5, UL8, UL52 and ICP8, or in 
cells infected with polymerase‑deficient HSV‑1, 
AAV‑2 DNA is replicated by cellular polymerases, 
but presumably only in the subset of cells that are 
in S phase. In summary, the helper functions pro‑
vided by both Ad and HSV‑1 helper viruses help 
AAV‑2 to overcome two major barriers to produc‑
tive replication: rep expression and DNA replica‑
tion. This is achieved by transactivation of the p5 
rep promoter and by facilitation of AAV‑2 DNA 
replication by direct participation of helper factors 
in AAV‑2 DNA replication and, in the case of Ad, 
additionally directing the host cell into S phase. 
An overview of the HSV‑1 helper functions for 
AAV‑2 replication is provided in TABle 1.
Interactions at the level of viral 
replication compartments
The presence of HSV‑1 helper factors during 
HSV/AAV hybrid vector replication and pack‑
aging not only leads to hybrid vector replication 
from the HSV‑1 ori, but also to AAV‑2 rep expres‑
sion and consequently to rescue and replication of 
the ITR‑flanked transgene cassette [1]. Studying 
the interaction of replicating HSV‑1 and AAV‑2 
DNA may therefore provide useful insight into 
the molecular mechanisms underlying the lower 
replication efficiency of HSV/AAV hybrid vec‑
tors compared with standard HSV‑1 amplicon 
vectors. Analogous to the situation with other 
DNA viruses, AAV‑2 DNA replication occurs in 
nuclear RCs, in which AAV‑2 DNA co localizes 
with Rep proteins and components of the DNA 
Table 1. HSV‑1 helper functions for AAV‑2 replication.
Helper effect on 
AAV‑2
HSV‑1 helper protein/complex
(encoding gene)
Expression 
kinetics
Function Ref.
rep gene expression E3 ubiquitin ligase ICP0
(RL2)
IE Activation of rep promoters
Rep68/78 and Rep40/52 synthesis
[135,137,138]
Transcriptional regulator ICP4
(RS1)
IE Synergistic effect with ICP0
Rep68/78 and Rep40/52 synthesis
[138]
Regulatory protein ICP22
(US1)
IE Synergistic effect with ICP0
Rep40/52 synthesis
[138]
DNA replication ssDNA-binding protein ICP8
(UL29)
Early Stabilization of ssDNA
Interaction with Rep68/78
[138,144,147,148]
Helicase–primase complex
(UL5/8/52)
Early Scaffold for HSV-1 replication complex
5’–3’ helicase activity
[138,144,148,150]
DNA polymerase holoenzyme
(UL30/42)
Early AAV DNA synthesis [8,120,138,144]
AAV-2: Adeno -associated virus type 2; HSV-1: Herpes simplex virus type 1; IE: Immediate-early.
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replication machinery [28,147,148,151]. AAV‑2 DNA 
replication initiates at small nuclear foci, so‑called 
pre‑replicative sites, which grow in size and appear 
to coalesce into large globular structures, eventu‑
ally filling out most of the nucleus and displac‑
ing cellular chromatin to the nuclear periph‑
ery [14,28,151]. In the case of Ad as the helper virus, 
AAV‑2 DNA initially colocalizes with Ad DNA, 
suggesting that AAV‑2 is recruited into Ad RCs 
[28]. However, while the AAV‑2 RCs develop into 
large globular structures, the maturation of the 
Ad RCs is inhibited by the presence of AAV‑2 [28]. 
In contrast to the situation with Ad, AAV‑2 and 
HSV‑1 helper viruses were shown to replicate in 
spatially separate RCs [152]. The RCs of AAV‑2 
and HSV‑1 could not only be distinguished by 
direct visualization of the viral DNA, but also 
by the set of viral and cellular proteins that they 
recruited. To directly visualize replicating AAV‑2 
and HSV‑1 DNA in live cells, rAAV‑2 plas‑
mids and HSV‑1 amplicon plasmids containing 
multiple lac operator and tetracycline operator 
repeats, respectively, were visualized by binding 
of lac repressor and tetra cycline repressor fused to 
autofluorescent proteins. Such visualization sys‑
tems allow time‑lapse analysis of viral RCs and, 
if combined with indirect immunofluorescence 
or transfection of fluorescently tagged replication 
factors, analysis of the set of proteins associated 
with the viral RCs [14,151,152]. Specifically, it was 
shown that the large Rep proteins are recruited 
into AAV‑2, but not into HSV‑1 RCs [152], an 
observation that can be readily explained by the 
presence of stronger RBSs in the AAV‑2 genome 
than in the HSV‑1 genome [153]. By simultane‑
ous visualization of AAV‑2 DNA replication 
from the alternative oris within the ITRs and 
the p5 promoter, it was previously shown that 
the degree of colocalization of Rep68 and Rep78 
proteins with replicating DNA substrates corre‑
lates with their affinity for the RBSs within the 
respective oris [14]. In contrast to Rep, the essen‑
tial helper factor ICP8 was demonstrated to be 
equally recruited into both AAV‑2 and HSV‑1 
RCs, although with differential staining patterns 
[152]. Specifically, ICP8 adopted a punctate stain‑
ing pattern within HSV‑1 RCs, consistent with 
binding to the ssDNA present at the replication 
forks, but not to the dsHSV‑1 replication products 
[152]. By contrast, ICP8 adopted a more diffuse 
pattern within AAV‑2 RCs, presumably reflecting 
binding of ICP8 to AAV‑2 replication forks, as 
well as to ssDNA on AAV‑2 replication products 
[152]. Similar to the situation for ICP8, the HSV‑1 
DNA polymerase catalytic subunit UL30 was 
shown to be recruited to both HSV‑1 and AAV‑2 
RCs, a finding that is consistent with the HSV‑1 
DNA polymerase being involved in AAV‑2 DNA 
replication [Glauser DL et al.,  Unpublished Data] [138]. 
The ICP4 transactivator protein, by contrast, was 
shown to be recruited more strongly into HSV‑1 
than into AAV‑2 RCs [152], consistent with strong 
binding of ICP4 to HSV‑1 DNA [81,154]. However, 
in the absence of replicating HSV‑1 DNA (i.e., in 
the presence of transfected HSV‑1 helper factors), 
ICP4 was recruited into AAV‑2 RCs, suggesting 
that ICP4 may also show weak binding to AAV‑2 
DNA [138]. Finally, RPA was shown to be hyper‑
phosphorylated and recruited into AAV‑2 RCs 
[148], while hyperphosphorylation of RPA was 
not induced during HSV‑1 replication and the 
low levels of endogenous hyper phosphorylated 
RPA were spatially excluded from HSV‑1 RCs 
by sequestration into virus‑induced chaperone‑
enriched domains [155,156]. RPA is a heterotrimeric 
ssDNA‑binding protein consisting of 70‑, 32‑ and 
14‑kDa subunits involved in diverse processes such 
as DNA replication, DNA repair, recombination 
and DNA damage signaling [157]. It is thought 
that RPA participates in AAV‑2 DNA replication 
and that it is recruited into AAV‑2 replication 
complexes by a direct interaction with Rep68 
and Rep78 [125,148]. The finding that AAV‑2 and 
HSV‑1 replicate in spatially independent RCs is 
consistent with the hypothesis that HSV‑1 and 
AAV‑2 RCs are clonal (i.e., derived from indi‑
vidual parental virus genomes) and that both the 
viral DNA and the associated proteins cannot 
freely move between individual RCs [14,81,158].
But what are the implications of these obser‑
vations for the reciprocal interactions between 
AAV‑2 and HSV‑1? The finding that the sites 
of AAV‑2 and HSV‑1 DNA replication are spa‑
tially separated implies that the spatial separa‑
tion also applies to the helper factors associated 
with AAV‑2 and HSV‑1 replication complexes. 
Since most of the HSV‑1 helper factors involved 
in AAV‑2 replication are also essential for HSV‑1 
replication, it is conceivable that their recruit‑
ment away from HSV‑1 RCs into AAV‑2 RCs 
might result in an inhibition of HSV‑1 replica‑
tion. Indeed, the maturation of HSV‑1 RCs is 
inhibited in the presence of replicating AAV‑2 
DNA [152]. The inhibitory effect of AAV‑2 on 
HSV‑1 does, however, not strictly depend on the 
presence of replicating AAV‑2 DNA. Instead, 
the mere presence of the large Rep proteins is 
sufficient for considerable inhibition of HSV‑1 
replication, suggesting that they have an intrin‑
sic ability to interfere with HSV‑1 DNA replica‑
tion [152]. The latter finding does not, however, 
exclude an additional role of competition for 
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replication factors in the inhibition of HSV‑1 
replication. Indeed, support for the hypothesis 
that AAV‑2 and HSV‑1 compete for replication 
factors stems from experiments where HSV‑1 
helper factors were provided by infection with 
a recombinant virus lacking the HSV‑1 ori‑
binding protein UL9 or by transfection of the 
HSV‑1 helper factors with or without UL9 [144]. 
Since UL9 is essential for HSV‑1 replication, 
but not for AAV‑2 replication, its absence spe‑
cifically prevents HSV‑1 replication while allow‑
ing AAV‑2 replication. Both in the situation of 
HSV‑1 infection and transfection of HSV‑1 
helper factors, the replication of AAV‑2 proceeds 
more efficiently in the absence of UL9, suggest‑
ing that the absence of HSV‑1 DNA replica‑
tion increases the availability of helper factors 
for AAV‑2 DNA replication [144]. It is therefore 
plausible that the presence of replicating AAV‑2 
DNA similarly limits the availability of essential 
replication factors for HSV‑1 replication. In sum‑
mary, DNA replication of AAV‑2 and that of its 
helper virus HSV‑1 occurs in spatially separate 
nuclear RCs that can be distinguished by the 
direct visualization of viral DNA, as well as by 
the set of viral and cellular proteins associated 
with them. It is thought that the spatial separa‑
tion of AAV‑2 and HSV‑1 DNA replication leads 
to some competition for replication factors essen‑
tial for both viruses such as the helicase–primase 
complex and ICP8, and that such competition 
may be involved in the inhibited replication of 
HSV‑1 in the presence of AAV‑2. However, the 
presence of Rep68 and Rep78 without replicat‑
ing AAV‑2 DNA is sufficient for significant inhi‑
bition of HSV‑1 RC maturation, suggesting that 
inhibition of HSV‑1 replication by AAV‑2 also 
involves a direct inhibitory effect of Rep proteins.
Effects of AAV‑2 Rep on HSV‑1 replication 
& the host cell
The abovementioned observation of inhibited 
HSV‑1 RC maturation in the presence of rep‑
licating AAV‑2 or AAV‑2 Rep68 and Rep78 
proteins [152] is corroborated by several other 
findings. Specifically, coinfection with AAV‑2, 
AAV‑3 or AAV‑5 was demonstrated to inhibit the 
accumulation of HSV‑1 DNA in a dose‑depend‑
ent manner [152,159]. In addition, it was shown 
that the expression of the AAV‑2 Rep proteins 
was sufficient for inhibition of ori of the short 
fragment (ori
S
)‑dependent HSV‑1 DNA replica‑
tion in transfected cells [160]. Consistent with 
these findings, the presence of the rep gene on 
HSV/AAV hybrid amplicon vectors was shown 
to result in significantly reduced titers of vector 
stocks [1]. Besides inhibiting HSV‑1 replication, 
AAV‑2 Rep has also been shown to have inhibi‑
tory effects on its other helper virus, Ad [28], as 
well as on the host cell [161,162]. The inhibitory 
effect of Rep on Ad has been suggested to occur 
primarily at the level of DNA replication [163], 
although several effects on Ad gene expression 
have also been demonstrated [164–167]. Although 
it is thought that the inhibitory effect of AAV‑2 
on its helper viruses contributes to the replica‑
tion fitness of AAV‑2 in coinfected cells, it can 
also lead to autoinhibition. Specifically, at very 
high AAV‑2 doses or high Rep expression levels, 
the inhibitory effect on Ad is so pronounced that 
it actually results in reduced levels of AAV‑2 rep‑
lication due to insufficient synthesis of Ad helper 
factors [168,169]. The inhibitory effects of Rep 
on the host cell include the induction of DNA 
damage, cell‑cycle arrest and apoptosis [170–172], 
implying that the effects of Rep on HSV‑1 and 
Ad replication may either be direct or else a 
consequence of the effects of Rep on the host 
cell. The molecular mechanisms underlying the 
inhibitory effect of Rep on HSV‑1 were addressed 
in a recent study [153]. Analysis of a panel of Rep 
proteins lacking defined domains and activities 
revealed that the inhibitory effect on HSV‑1 
replication required the Rep DNA‑binding and 
ATPase/helicase activities. Specifically, while 
Rep78 strongly inhibited HSV‑1 replication, the 
inhibitory activity was lost for Rep52 lacking 
the N‑terminal DNA‑binding and endonuclease 
domains, as well as for a mutant Rep78 protein, 
Rep78(K340H), lacking ATPase/helicase activ‑
ity due to a mutated NTP‑binding site [153]. By 
contrast, Rep68, which lacks the C‑terminal 
domain of Rep78, as well as a mutant Rep78 
protein that has no endonuclease activity [173,174], 
inhibited HSV‑1 replication just as strongly as 
the full‑length Rep78 protein [153]. In addition, 
it was found that the DNA‑binding activity and 
the ATPase/helicase activity need to be present on 
the same Rep molecule, since trans‑complemen‑
tation of Rep DNA‑binding and ATPase/helicase 
activities did not restore the inhibitory effect 
[153]. Together, these findings suggest that Rep 
DNA‑binding and ATPase/helicase activities, 
but not endonuclease activity, are required for 
the inhibitory effect on HSV‑1 replication, and 
that both activities need to be present on the same 
Rep molecule. Rep78 had a moderate inhibitory 
effect on HSV‑1 IE and early gene expression, 
but a strong inhibitory effect on HSV‑1 DNA 
replication and late gene expression. Although 
Rep78 moderately reduced HSV‑1 early gene 
expression, this effect was shown not to account 
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for the reduced HSV‑1 DNA replication, sug‑
gesting that Rep78 was directly interfering with 
HSV‑1 DNA replication [153]. Intriguingly, the 
Rep activities required for inhibition of HSV‑1 
replication precisely coincided with those respon‑
sible for induction of DNA damage and apopto‑
sis [153,172]. However, preventing the execution of 
apoptosis with caspase inhibitors did not prevent 
the inhibition of HSV‑1 replication, nor did Rep 
induce apoptosis in HSV‑1‑infected cells, together 
suggesting that the execution of apoptosis is not 
involved in the inhibitory effect on HSV‑1 [153]. 
The DNA damage response elicited by Rep68 
and Rep78 is characterized by hyperphosphoryla‑
tion of ATM, RPA32, Chk2 and H2AX, with 
the activation of H2AX depending on ATM 
function [153,170]. By contrast, HSV‑1 infection 
induces activation of ATM, Chk2 and H2AX, 
but not of RPA [155,156,175,176]. The low levels of 
endogenous hyperphosphorylated RPA are even 
sequestered away from HSV‑1 RCs into virus‑
induced chaperone‑enriched domains [155,156], 
suggesting that they may be inhibitory to HSV‑1 
replication. It was therefore hypothesized that 
activation of RPA by Rep might be responsible 
for inhibition of HSV‑1 replication. However, 
hyperphosphorylation of RPA induced by other 
means, such as camptothecin or infection with 
UV‑inactivated AAV‑2 [177,178], did not reduce 
HSV‑1 replication, suggesting that the activation 
of RPA per se is not involved in the inhibitory 
effect of Rep on HSV‑1 [153]. It therefore appears 
that the ability of Rep to induce DNA damage, 
rather than the cellular response to it, is responsi‑
ble for the inhibitory effect on HSV‑1. Although 
the currently available data suggest that Rep‑
induced DNA damage, cell‑cycle arrest, apopto‑
sis and inhibition of HSV‑1 are mediated by the 
binding of Rep to degenerate RBSs within the 
cellular and HSV‑1 DNA followed by unwind‑
ing via the ATPase/helicase activity [153,170,172], 
the exact mechanisms by which Rep induces the 
DNA damage remain unsolved. Since Rep endo‑
nuclease activity is not required for the induc‑
tion of DNA damage [153], it remains somewhat 
unclear how Rep DNA binding and unwinding 
results in an activation of ATM, which is con‑
sidered to be a marker for double‑strand breaks 
(DSBs) [179]. However, a recent report on the Rep 
homolog of parvovirus H‑1, NS1, showed that 
NS1‑induced DNA damage, cell‑cycle arrest and 
apoptosis are mediated by the accumulation of 
reactive oxygen species (ROS) known to result 
in DSBs [180]. The NS1 activities involved in the 
induction of ROS remain unknown [180], and it 
is therefore difficult to speculate about a possible 
mechanism. Nonetheless, it is possible that NS1 
stimulates the expression of genes involved in 
ROS production or in the regulation of ROS 
homeostasis and that this is responsible for the 
observed DNA damage and the resulting cell‑
cycle arrest and apoptosis [180]. It is tempting to 
speculate that AAV‑2 Rep induces DSBs through 
a similar mechanism and that this accounts for 
the observed DNA damage response, cell‑cycle 
arrest, apoptosis and inhibition of HSV‑1 replica‑
tion. However, further clarification of this issue 
awaits an experimental assessment of the role of 
ROS in AAV‑2 Rep‑induced DNA damage.
Conclusion & future perspective
On the analysis of AAV–HSV interactions
The fact that AAV‑2 can only productively repli‑
cate in cells that are coinfected with a helper virus 
inevitably leads to a complex network of inter‑
actions between AAV‑2, the helper virus and the 
host cell. A successful replication strategy for 
AAV‑2 must allow efficient expression of the helper 
factors while ensuring that the replication of the 
helper virus does not proceed unchecked in order 
to limit competition for helper factors and cellular 
resources. Indeed, AAV‑2 is thought to allow the 
efficient expression of HSV‑1 IE genes, including 
the helper factors ICP0, ICP4 and ICP22, which 
are important to trans activate AAV‑2 rep gene 
expression [135,138,152]. The HSV‑1 IE gene prod‑
ucts simultaneously transactivate HSV‑1 early 
gene expression, resulting in the synthesis of a 
second set of helper factors, the ssDNA‑binding 
protein ICP8, the helicase–primase complex and 
the DNA polymerase holoenzyme [138,144]. These 
helper factors are then thought to be recruited to 
the AAV‑2 oris by a direct interaction of the large 
Rep proteins with ICP8 and to provide the repli‑
cation machinery for AAV‑2 DNA replication, the 
latter proceeding in RCs spatially separated from 
those of the helper virus [120,147,148,152]. The large 
Rep proteins also seem to have an intrinsic ability 
to inhibit the replication of cellular and HSV‑1 
DNA, which is dependent on their DNA‑binding 
and ATPase/helicase activities [152,153,160,170]. By 
interfering with HSV‑1 DNA replication, AAV‑2 
is thought to limit the competition of HSV‑1 DNA 
for the HSV‑1 replication machinery. Although 
the currently available data provide important 
clues in support of such a model, many aspects 
still remain elusive. Of particular interest are the 
molecular mechanisms by which Rep seems to 
selectively interfere with the replication of cellular 
and HSV‑1 DNA while allowing efficient AAV‑2 
DNA replication. It is plausible that such specifi‑
city is simply based on the fact that, within the 
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AAV‑2 genome, the Rep proteins are specifically 
targeted to the ITRs and p5 oris, where they ful‑
fill an essential function for the repair synthesis 
of the ITRs [145]. However, at high Rep concen‑
trations, Rep binding to degenerate cellular and 
HSV‑1 RBSs occurs at random locations, where 
it potentially interferes with DNA replication and 
transcription. A crucial point in understanding 
the effects of Rep on HSV‑1 and the cell appears 
to be the understanding of the mechanism by 
which Rep induces DNA damage. In light of the 
recent finding that this does not require Rep endo‑
nuclease activity [153], this mechanism seems to be 
more complicated than was previously thought 
[170]. However, very recent findings about the Rep 
homolog NS1 of parvovirus H‑1 demonstrate that 
NS1‑induced DNA damage, cell‑cycle arrest and 
apoptosis are mediated by the induction of ROS, 
suggesting that NS1 may induce expression of 
genes involved in ROS production or in regula‑
tion of ROS homeostasis [180]. Whether a similar 
mechanism is involved in AAV‑2 Rep‑induced 
DNA damage, cell‑cycle arrest, apoptosis and 
inhibition of HSV‑1 remains to be determined 
in future studies.
On HSV/AAV hybrid vector design
The ability of Rep to interfere with HSV‑1 
DNA replication has so far hampered the effi‑
cient production of HSV/AAV hybrid amplicon 
vectors [181]. To circumvent this problem, sev‑
eral approaches are possible, some of which have 
been addressed experimentally:
n	The design of HSV/AAV hybrid amplicon vec‑
tors that restrict rep expression to the time 
frame from transduction to site‑specific inte‑
gration: specifically, the HSV/AAV hybrid 
vectors were designed in such a way that little 
or no rep was expressed during vector replica‑
tion and packaging. However, rep was 
expressed in transduced cells expressing Cre‑
recombinase. Following site‑specific integra‑
tion, rep was suppressed again in order to 
increase the stability of the integrated trans‑
gene [182]. The major drawback of this 
approach, however, is its dependence on Cre‑
recombinase‑expressing target cells, making it 
unfeasible for in vivo treatments; 
n	The incorporation of chimeric rep genes 
encoding Rep proteins with pharmacologi‑
cally controllable activity: in this scenario, 
Rep could be kept inactive during the vector 
replication/packaging process and pharmaco‑
logically activated during gene delivery, thus 
allowing site‑specific transgene integration. In 
a study by Rinaudo et al., it was shown that 
Rep activity can be made ligand‑dependent by 
the fusion of Rep to a truncated form of the 
hormone‑binding domain of the human pro‑
gesterone receptor, which can be specifically 
activated by the synthetic progesterone recep‑
tor antagonist RU486 [183]. This chimeric Rep 
protein mediates site‑specific integration in a 
ligand‑dependent manner, and thus represents 
a suitable candidate for incorporation into 
HSV/AAV hybrid vectors; 
n	The incorporation of mutant rep genes that 
support AAV‑2 site‑specific integration but do 
not inhibit hybrid vector replication: since the 
inhibition of HSV‑1 replication is mediated by 
Rep’s DNA‑binding and ATPase/helicase 
activities [153], both of which are required for 
AAV‑2 DNA replication and site‑specific inte‑
gration, this approach seems not to be straight‑
forward. Nonetheless, we have recently been 
able to identify a mutant Rep78 protein that 
supports AAV‑2 DNA replication, but does not 
signif icantly inhibit HSV‑1 replication 
[Glauser DL et al., Unpublished Data]. We are cur‑
rently analyzing how the biochemical activities 
of this mutant differ from those of wild‑type 
Rep78, and if this mutant is able to support 
efficient HSV/AAV hybrid vector replication 
and site‑specific integration; 
n	The design of HSV/AAV amplicon vectors that 
replicate from an AAV‑2 instead of an HSV‑1 
ori: since Rep selectively inhibits DNA replica‑
tion from HSV‑1 oris while allowing efficient 
replication from AAV‑2 oris [153], an HSV/AAV 
amplicon vector in which the HSV‑1 ori
S
 is 
replaced by an AAV‑2 ori (p5 or ITR) has the 
potential to replicate to high titers in the pres‑
ence of Rep proteins. Indeed, a HSV/AAV 
hybrid amplicon vector containing the AAV‑2 
p5 ori and the HSV‑1 pac signal is replicated 
and packaged into HSV‑1 virions in the pres‑
ence of HSV‑1 helper factors [14]. However, the 
efficiencies of vector production and site‑spe‑
cific integration compared with conventional 
HSV/AAV hybrid amplicon vectors remain to 
be determined;
n	The incorporation of Rep proteins into the 
HSV‑1 particle by fusion to the HSV‑1 VP16 
tegument protein: in this approach, the full‑
length AAV‑2 rep gene is fused to the C‑termi‑
nus of full‑length HSV‑1 UL48 (encoding 
VP16) in the packaging‑deficient helper DNA 
(fHSVDpacD27Dkn). Notably, this approach 
is different from previously described 
www.futuremedicine.com 495future science group
Interactions between AAV-2 & HSV-1: implications for hybrid vector design Review
Rep–VP16 chimeras, in which the DNA‑bind‑
ing domain of Rep was fused to the VP16 acti‑
vation domain in a study concerned with in 
vivo analysis of Rep DNA binding [184]. During 
the vector replication/packaging process, the 
VP16–Rep fusion protein is synthesized and 
incorporated into the vector particle, while the 
corresponding fusion gene remains unpackaged 
due to the packaging‑deficiency of the helper 
DNA. As the VP16–Rep fusion proteins would 
be synthesized late in HSV‑1 infection (VP16 
is expressed with leaky late [g1] expression 
kinetics), this would lead to only minimal inhi‑
bition of vector DNA replication. Upon trans‑
duction of the target cell, the VP16–Rep fusion 
is expected to be released from the virion and 
translocated to the nucleus, where it potentially 
mediates the site‑specific integration of the 
HSV/AAV hybrid vector DNA. We have 
assessed the feasibility of this approach and 
have successfully created HSV‑1 helper 
genomes bearing the corresponding fusion pro‑
tein. Although such helper DNA supports the 
replication and packaging of HSV/AAV hybrid 
amplicon vectors, the efficiency of site‑specific 
vector integration remains to be determined 
[Fraefel C, Unpublished Data].
In summary, while the ability of the large 
AAV‑2 Rep proteins to inhibit HSV‑1 DNA 
replication confers to AAV‑2 a competitive 
advantage over HSV‑1 during coinfection, 
it poses a significant problem for HSV/AAV 
hybrid vector design in that it hampers effi‑
cient hybrid vector production. Several strate‑
gies have been addressed to circumvent this 
problem, including controlling the expression 
or activity of Rep during vector production, the 
incorporation of mutant rep genes with reduced 
inhibitory effects on HSV‑1, the replication of 
hybrid vector genomes from AAV‑2 instead 
of HSV‑1 replication origins and, finally, the 
incorporation of the Rep protein into the 
hybrid vector particle by fusion to VP16 tegu‑
ment protein. Although research into most of 
these approaches is still in its early phases, sev‑
eral feasible strategies seem to have emerged. 
Whether one of them will ultimately lead to 
the development of optimal HSV/AAV hybrid 
amplicon vectors replicating to high titers and 
mediating efficient and stable site‑specific inte‑
gration with concomitant long‑term in vivo 
transgene expression remains to be shown; 
however, it certainly seems that this aim will 
become achievable in the near future.
Executive summary
Herpes simplex virus type 1
n	Herpes simplex virus type 1 (HSV-1) is a member of the Herpesviridae family. Its genome is a dsDNA of 150 kbp that encodes more than 
85 proteins.
n	HSV-1 has been used for the construction of two fundamentally different types of gene therapy vectors. Recombinant HSV-1 vectors 
are created by replacing one or several virus genes with transgene sequences. HSV-1 amplicon vectors are bacterial plasmids that 
contain two cis elements from the HSV-1 genome, an origin of DNA replication and a DNA packaging/cleavage signal; they have a 
transgene capacity of up to 150 kbp. Amplicon vectors depend on helper functions for replication and packaging.
Adeno‑associated virus type 2 
n	Adeno-associated virus type 2 (AAV-2) is a member of the Parvoviridae family. Its genome is a ssDNA of 4.7 kb that encodes eight 
proteins. AAV-2 can establish latent infections by genomic integration, preferentially at AAVS1 on human chromosome 19.
n	AAV-2-based gene therapy vectors are created by replacing the viral rep and cap genes with transgene sequences. AAV-2 vectors 
depend on helper functions for replication and packaging.
HSV/AAV hybrid vectors
n	HSV/AAV hybrid vectors have been constructed to combine the large transgene capacity of HSV-1 with the potential for site-specific 
genomic integration and long-term transgene expression of AAV-2. 
Replication compartment
n	DNA viruses replicate in specialized subnuclear structures, termed replication compartments, in which virus DNA colocalizes with viral 
and cellular components of the DNA replication machinery. 
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